Lara King
Nurse Practitioner · Meridian, MSNPI 1679857932
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.8%), speaking fees and education — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Insulet Corporation at 47.7% of the total. 2025 is the largest year on record at $4,502, 3.0 times the $1,505 reported in 2021. Among nurse practitioner clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 195 payments — averaging $40.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$4K
- AstraZeneca$1K
- Novo Nordisk$475
- Lilly USA, LLC$445
- Boehringer Ingelheim$426
- Bayer$360
- plus $1K from 12 others
What the payments were for
- Speaking & faculty fees$3,70047%
- Food & beverage$4,15153%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insulet Corporation | 13 | $3,753 |
| AstraZeneca | 40 | $1,332 |
| Novo Nordisk | 39 | $475 |
| Lilly USA, LLC | 30 | $445 |
| Boehringer Ingelheim | 17 | $426 |
| Bayer | 12 | $360 |
| Abbott | 16 | $288 |
| Corcept Therapeutics | 8 | $242 |
| Amgen | 3 | $153 |
| Medtronic | 2 | $106 |
| Merck | 6 | $104 |
| Dexcom, Inc. | 3 | $53 |
| Boston Scientific | 1 | $35 |
| Averitas Pharma Inc. | 1 | $24 |
| Tandem Diabetes Care, Inc. | 1 | $21 |
| Blue Earth Diagnostics | 1 | $18 |
| GRT US Holding, Inc. | 1 | $15 |
| Valinor Pharma, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,863 in reported general payments places this provider in the 95th percentile of 1,090 nurse practitioner providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 301 | $510,253 |
| MounjaroTirzepatide | 185 | $270,094 |
| FarxigaDapagliflozin Propanediol | 254 | $247,654 |
| JardianceEmpagliflozin | 178 | $223,654 |
| TrulicityDulaglutide | 93 | $129,943 |
| Tresiba Flextouch U-100Insulin Degludec | 153 | $89,946 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 51 | $59,237 |
| RybelsusSemaglutide | 46 | $53,249 |
| Xigduo XrDapaglifloz Propaned/Metformin | 36 | $49,223 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 44 | $40,106 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 47 | $37,283 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 53 | $36,170 |
| SynjardyEmpagliflozin/Metformin Hcl | 30 | $34,004 |
| Tresiba Flextouch U-200Insulin Degludec | 35 | $29,559 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 103 | $24,233 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $475 | $570,255374 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $445 | $403,028291 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy | $426 | $316,895259 claims |
| AstraZenecaFarxiga | $1,332 | $247,654254 claims |
| MerckJanuvia | $104 | $16,87026 claims |
| BayerKerendia | $360 | $8,72013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,090 nurse practitioner providers in Mississippi.
Other nurse practitioner in Meridian
- Christina TreppendahlRidgeland$125K
- Jo Anna WarrenJackson$73K
- Marisa StringerBiloxi$68K
- Sara KlausFlowood$48K
- Micaela PerkinsOxford$32K
- Michelle TharpJackson$28K
- Kaylon LewisHattiesburg$25K
- Jennifer HollyJackson$16K
- Mariah CoxGulfport$14K
- Brittany HicksGulfport$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.